About Be Bio
Be Bio is a company based in Cambridge (United States) founded in 2020.. Be Bio has raised $356 million across 4 funding rounds from investors including Takeda Pharmaceuticals, RA Capital and Arch Venture Partners. Be Bio offers products and services including B Cell Medicines and Research Platform. Be Bio operates in a competitive market with competitors including Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$356 M (USD)
in 4 rounds
-
Latest Funding Round
$92 M (USD), Series C
Jan 15, 2025
-
Investors
Takeda Pharmaceuticals
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Be Bio
Be Bio offers a comprehensive portfolio of products and services, including B Cell Medicines and Research Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered treatments for serious diseases like hemophilia B
Tools for advancing B cell therapies through publications
Unlock access to complete
Unlock access to complete
Funding Insights of Be Bio
Be Bio has successfully raised a total of $356M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $92 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $92.0M
-
First Round
First Round
(22 Oct 2020)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series C - Be Bio | Valuation | Nextech Invest | |
| Oct, 2024 | Amount | Series B - Be Bio | Valuation |
investors |
|
| Apr, 2022 | Amount | Series B - Be Bio | Valuation | Arch Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Be Bio
Be Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, RA Capital and Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Be Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Be Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Be Bio Comparisons
Competitors of Be Bio
Be Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
B cells are programmed as biofactories for therapeutic protein delivery.
|
|
| domain | founded_year | HQ Location |
Cell immunotherapy products are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Cell-based therapeutics for cancer and immunological disorders are developed.
|
|
| domain | founded_year | HQ Location |
-
|
|
| domain | founded_year | HQ Location |
B cell-based therapies are developed for autoimmunity, immunodeficiency, and cancers.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Be Bio
Frequently Asked Questions about Be Bio
When was Be Bio founded?
Be Bio was founded in 2020.
Where is Be Bio located?
Be Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Be Bio a funded company?
Be Bio is a funded company, having raised a total of $356M across 4 funding rounds to date. The company's 1st funding round was a Series B of $130M, raised on Oct 22, 2020.
What does Be Bio do?
Be Bio was founded in 2020 in Cambridge, United States, and operates in the biotechnology sector. Proprietary autologous and allogeneic BeCM platforms are utilized to advance B cell therapies across oncology and rare diseases. Pipeline candidates are progressed in these areas, while the platform is extended to infectious diseases, neurological conditions, and autoimmune diseases.
Who are the top competitors of Be Bio?
Be Bio's top competitors include Immusoft, JW Therapeutics and Walking Fish Therapeutics.
What products or services does Be Bio offer?
Be Bio offers B Cell Medicines and Research Platform.
Who are Be Bio's investors?
Be Bio has 8 investors. Key investors include Takeda Pharmaceuticals, RA Capital, Arch Venture Partners, Atlas Venture, and Bristol-Myers Squibb.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.